N-hexanoyl-sphingomyelin potentiates in vitro doxorubicin cytotoxicity by enhancing its cellular influx.
D000230:Adenocarcinoma; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000493:pharmacokinetics* / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000473:pathology; D016923:Cell Death; D002462:Cell Membrane; D004058:Diffusion; D004317:Doxorubicin / Q000493:pharmacokinetics* / Q000494:pharmacology*; D016503:Drug Delivery Systems; D004347:Drug Interactions; D004357:Drug Synergism; D042783:Endothelial Cells; D005347:Fibroblasts; D006801:Humans; D051379:Mice; D018345:Mice, Knockout; D013109:Sphingomyelins / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
D000903:Antibiotics, Antineoplastic; D013109:Sphingomyelins; D004317:Doxorubicin